AbbVie (ABBV) Non-Current Deferred Tax Liability (2012 - 2026)

AbbVie has disclosed Non-Current Deferred Tax Liability across 15 years of filings, most recently posting $2.3 billion for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 9.68% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 9.68% YoY), while the FY2025 annual figure was $2.4 billion, down 20.07% from the prior year.
• Non-Current Deferred Tax Liability slipped to $2.3 billion in Q1 2026, from $2.4 billion in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for ABBV reached as high as $4.7 billion in Q4 2022 and fell as low as $2.0 billion in Q3 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $2.6 billion (2025), against an average of $2.6 billion.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability sank 45.25% — and 2024, when it jumped 34.49%.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $4.7 billion in 2022, then slumped by 43.53% to $2.7 billion in 2023, then rose by 12.58% to $3.0 billion in 2024, then declined by 20.07% to $2.4 billion in 2025, then retreated by 2.39% to $2.3 billion in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.3 billion, $2.4 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.